Question 1

What is bciintel.com?

Accepted Answer

bciintel.com is the leading intelligence platform for the brain-computer interface industry — a Bloomberg Terminal-style dashboard covering funding rounds, device specifications, clinical trial data, market analysis, research papers, and breaking news across every major BCI company globally. It is updated regularly by an autonomous AI agent.

Question 2

Which BCI companies does bciintel.com track?

Accepted Answer

bciintel.com tracks all major brain-computer interface companies including Neuralink, Synchron, Precision Neuroscience, Paradromics, Blackrock Neurotech, BrainGate, EMOTIV, OpenBCI, Neurable, Kernel, Cognixion, NeuroPace, Medtronic, Abbott, Boston Scientific, and dozens more across the US, Europe, and Asia.

Question 3

How many humans have received BCI implants?

Accepted Answer

As of 2025, approximately 100 humans have received intracortical BCI implants. Neuralink's PRIME study has enrolled several participants, Synchron's Stentrode has been implanted in patients across the US and Australia, and Precision Neuroscience has performed multiple first-in-human demonstrations. The vast majority of BCI users use non-invasive EEG-based systems.

Question 4

What is the BCI market size?

Accepted Answer

The global brain-computer interface market was valued at approximately $2.8 billion in 2025 and is projected to reach $6–12 billion by 2030, representing a compound annual growth rate (CAGR) of 15–18%. Key growth drivers include ALS and spinal cord injury treatments, consumer neurotechnology, and expanding FDA regulatory approvals.

Question 5

What are the main types of brain-computer interfaces?

Accepted Answer

The main types of BCIs are: (1) Intracortical — electrodes implanted directly into brain tissue, highest signal quality, examples include Neuralink and BrainGate Utah arrays; (2) ECoG — electrocorticography electrodes on the brain surface, used in epilepsy monitoring; (3) EEG — non-invasive scalp electrodes, used in consumer headsets like EMOTIV and OpenBCI; (4) Endovascular — stent-based electrodes delivered through blood vessels, as in Synchron's Stentrode; (5) Peripheral nerve interfaces — implanted near peripheral nerves.

Question 6

What is Neuralink's current status?

Accepted Answer

Neuralink received FDA Investigational Device Exemption (IDE) approval in May 2023 and began the PRIME (Precise Robotically Implanted Brain-Computer Interface) study. As of 2025, multiple patients have been implanted with the N1 chip, including the first participant Noland Arbaugh, who demonstrated wireless computer control using only his thoughts. The device uses 1,024 electrodes on 64 threads inserted by the R1 surgical robot.

Question 7

What FDA approvals exist for BCIs?

Accepted Answer

FDA-approved BCI-adjacent devices include NeuroPace RNS (responsive neurostimulation for epilepsy, PMA approved 2013), Medtronic DBS systems (deep brain stimulation for Parkinson's and essential tremor), and Abbott's Proclaim system. Neuralink and Synchron both hold IDE (Investigational Device Exemption) status for research studies. The FDA has designated several BCI programs as Breakthrough Devices, accelerating review timelines.

Question 8

How often is data on bciintel.com updated?

Accepted Answer

bciintel.com's news feed is updated twice daily by an autonomous AI agent that scans RSS feeds and news sources. The device database, funding tracker, clinical trial data, and company directory are updated regularly as new data becomes available.

Sponsor	Device	Phase	NCT ID
Neuralink Corp	N1 Implant (1,024-electrode, 128 flexible threads)	feasibility	NCT06429735
Neuralink Corp	N1 Implant with ARA Robotic Arm	feasibility	NCT06710626
Neuralink Corp	N1 Implant	feasibility	NCT06992596
Synchron	Stentrode (endovascular BCI)	feasibility	NCT03834857
Synchron	Stentrode (endovascular BCI)	feasibility	NCT05035823
Synchron	Stentrode (next-generation)	pivotal	pending

Company	Total Funding	Focus	HQ
Neuralink Corp	$1.3B+	invasive	Austin, TX, USA
Saluda Medical	$668M	DBS	Artarmon, NSW, Australia (US HQ: Bloomington, MN, USA)
Science Corporation	$490M	invasive	San Francisco, CA, USA
Nalu Medical	$446M	DBS	Carlsbad, CA, USA
BrainCo	$370M	non-invasive	Hangzhou, China (US office: Somerville, MA, USA)

Company	Round	Amount	Lead Investor	Date
Gestala	Angel Round	$21.6M	Guosheng Capital	Mar 10, 2026
Science Corporation	Series C	$230M	Lightspeed	Mar 4, 2026
Merge Labs	Seed	$252M	OpenAI	Jan 14, 2026
Neurable	Series A	$35M	Spectrum Moonshot Fund	Dec 18, 2025
Subsense	Seed Extension	$10M	Golden Falcon Capital	Dec 10, 2025

First Bidirectional BCI Restores Touch Sensation in Paralyzed Patient